[ad_1]

The U.S. Food and Drug Administration announced Friday that it has determined that the weight loss drug WeGoBe can reduce the risk of heart attack, stroke, and cardiovascular disease in overweight or obese adults.

As previously reported, dallas express, the popular weight loss drug Wegovy, and other semaglutide drugs such as Ozempic and Libersus have become popular for their purported ability to aid weight loss, despite their original purpose of treating type 2 diabetes. The increased usage is said to have even led to a decline in food sales at some grocery stores.

“Wegovy is the first weight loss drug approved for use in the prevention of life-threatening cardiovascular events in obese or overweight adults with cardiovascular disease,” said John Sharetz, director of the FDA’s Center for Drug Evaluation and Research. the doctor said. According to a press release, it is effective in preventing diabetes, dyslipidemia, and obesity. “This patient population is at increased risk for cardiovascular death, heart attack, and stroke. Providing treatment options proven to reduce this cardiovascular risk is a major advance for public health.”

The FDA’s decision, made at the request of Novo Nordisk, the maker of Wegovy, has a major impact on consumers because the drug is often considered for overweight and obese people who are at higher risk for cardiovascular disease. It is possible to give

“The hope is that insurance companies will start to understand that this is not a vanity drug,” said Dr. Martha Gulati, a cardiologist at Cedars-Sinai Medical Center in Los Angeles, according to the Associated Press. She said approximately 70% of such patients could be eligible for the prescription.

Still, the FDA says Wegovy users are at risk for potential “inflammation of the pancreas (pancreatitis), gallbladder problems (including gallstones), hypoglycemia, acute kidney injury, hypersensitivity reactions, and diabetic retinopathy (damage to the retina of the eye).” He pointed out the need to be careful. ), increased heart rate, suicidal behavior or thoughts. ”

Additionally, common side effects include “nausea, diarrhea, vomiting, constipation, abdominal (stomach) pain, headache, fatigue, dyspepsia (indigestion), dizziness, bloating, belching, and hypoglycemia in diabetic patients.” Includes blood sugar (hypoglycemia). , bloating (gas accumulation) and gastroesophageal reflux disease (heartburn). ”

CDC data suggests that obesity rates among adults will rise alarmingly in several states in 2022. A total of 22 states, including Texas, have adult obesity rates of 35% or higher. Obesity increases your risk of heart disease, type 2 diabetes, stroke, heart attack, and cancer.

As previously reported, dallas expressresearch shows semaglutide’s effects may plateau when it comes to weight loss, and experts say healthy eating and exercise remain important habits to help fight obesity and cardiovascular disease. I advise.

Please support our nonprofit journalism



[ad_2]

Source link